Tools for Disease Area Strategy

Disease Area Scan

Our “Disease Area Scan” tools compare key criteria across candidate indications, agnostic of new drug profiles.  We begin by characterizing each population’s unmet medical need, population size, and competitive intensity.

After identifying the indications that appear attractive from this assessment, we use heat maps to convey what levels of improvement in efficacy and safety will correspond to certain levels of clinical innovation and patient-share potential. These heat maps provide a useful way to guide the TPP building process.

Indication Prioritization

When a new drug is believed to have potential across multiple patient segments, our “Indication Prioritization” tools help clients identify in which populations/indications the asset has the greatest commercial outlook. Clients use these tools to determine which of those indications they should focus on for initial approval. We provide a variety of comparative views that characterize the asset across the populations by level of unmet medical need, clinical improvement vs. the standard of care (providing insight into patient share outlook), the population size, and competitive intensity.